Efficacy and Safety of Monotherapy with Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Compared with Adalimumab Monotherapy in Biologic-Naive Patients with Active Rheumatoid Arthritis: Results of a Global, Randomized, Double-Blind, Parallel-Group, Phase 3 Study

被引：0

作者：

Taylor, Peter C. ^{[1
]}

Schiff, Michael ^{[2
]}

Wang, Qingmin ^{[3
]}

Jiang, Yusang ^{[3
]}

Kurrasch, Regina ^{[4
]}

Daga, Shruti ^{[5
]}

Rao, Ravi ^{[6
]}

Hsu, Benjamin ^{[3
]}

Tak, Paul-Peter ^{[7
]}

机构：

[1] Univ Oxford, Kennedy Inst Rheumatol, NDORMs, Oxford, England

[2] Univ Colorado, Sch Med, Denver, CO USA

[3] Janssen Res & Dev LLC, Spring House, PA USA

[4] GlaxoSmithKline, Collegeville, PA USA

[5] GlaxoSmithKline, Uxbridge, Middx, England

[6] GSK Med Res Ctr, Stevenage, Herts, England

[7] GlaxoSmithKline, Stevenage, Herts, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3222

引用

页数：3

共 50 条

[31] Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Cohen, Stanley B.
Genovese, Mark C.
Choy, Ernest H.
Perez-Ruiz, Fernando
Pablos, Jose L.
Zhang, Nan
Kaur, Primal
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[32] Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Peterson, Steve
Pacou, Maud
Belhadi, Drifa
Van Sanden, Suzy
Webb, Thomas
Ganguly, Rita
Kurrasch, Regina
Rao, Ravi
Hsu, Benjamin
Fei, Kaiyin
Kielar, Danuta
Alfonso, Rafael
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[33] Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Fiore, Stefano
Genovese, Mark
Fan, Chunpeng
Decktor, Dennis
Fleischmann, Roy
JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1217 - 1217
[34] Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial
Tanaka, Yoshiya
Bingham, Clifton, III
Aletaha, Daniel
Agarwal, Prasheen
Popik, Sharon
Kurrasch, Regina
Peterson, Steve
Ganguly, Rita
Han, Chenglong
McQuarrie, Kelly
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[35] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Hsu, B.
Sheng, S.
Smolen, J. S.
Weinblatt, M. E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
[36] A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Wiland, Piotr
Jeka, Slawomir
Dokoupilova, Eva
Miranda Limon, Juan Manuel
Jauch-Lembach, Julia
Thakur, Anjali
Haliduola, Halimuniyazi
Gaylis, Norman B.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[37] Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Genovese, Mark C.
Jarosova, Katerina
Cieslak, Dorota
Alper, Jeffrey
Kivitz, Alan
Hough, Douglas R.
Maes, Peter
Pineda, Lilia
Chen, Mindy
Zaidi, Farrukh
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (07) : 1703 - 1710
[38] THE MUSASHI STUDY: COMPARISON OF SUBCUTANEOUS TOCILIZUMAB MONOTHERAPY VERSUS INTRAVENOUS TOCILIZUMAB MONOTHERAPY: RESULTS FROM A DOUBLE-BLIND, PARALLEL-GROUP, COMPARATIVE PHASE III NON-INFERIORITY STUDY IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
Ogata, A.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 373 - 373
[39] Long-Term Effect of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Karpouzas, George
Takeuchi, Tsutomu
Thorne, Carter
Sheng, Shihong
Kurrasch, Regina
Fei, Kaiyin
Hsu, Benjamin
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[40] WORK PRODUCTIVITY AND GENERAL HEALTH STATUS IMPROVEMENTS WITH SIRUKUMAB, AN ANTI-IL-6 CYTOKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TNF THERAPY: RESULTS FROM THE PHASE 3 SIRROUND-T STUDY
Tanaka, Y.
Aletaha, D.
Peterson, S.
Ganguly, R.
Kurrasch, R.
Popik, S.
Agarwal, P.
Li, N.
VALUE IN HEALTH, 2017, 20 (05) : A149 - A149

← 1 2 3 4 5 →